Gilead Slips As Former Bull Turns Bearish On Hep C Business

Shares of Gilead Sciences are sliding after Leerink analyst Geoffrey Porges downgraded the stock to Market Perform, saying he is now "outright bearish" on the company's Hepatitis C virus business.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.